The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated statistically significant reductions compared to placebo in mean monthly migraine days (MMDs) within the first 4 weeks, in...
Hence then, the article about new data demonstrates robust efficacy of vyepti eptinezumab in otherwise difficult to treat patients with severe migraine was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine )
Also on site :
- Spain’s FA condemns Islamophobic chants during game with Egypt
- Teenagers wreak havoc in Clapham during Easter holiday ‘link up’
- Politics latest: Starmer to deliver cost of living update after latest Trump tirade over Iran war